EUVIMEDEUVIMED entdecken
Fallbericht

Novel Pathogenic GCH1 Variant in Familial DOPA-Responsive Dystonia

Johanna Engel iD, Ivana Dzinovic, Michael Zech, Wibke G Janzarik iD

Neuropediatrics · 01.02.2026 · 57 (01) · 065-068

DOI: 10.1055/a-2747-7443 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Neuropediatrics, erschienen am 01.02.2026. Verfasst von Johanna Engel und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatric Neurology and Muscle Disorders, University Hospital Freiburg, Freiburg, Germany. Hauptthemen laut MEDLINE: GTP Cyclohydrolase, Dystonic Disorders. Die Arbeit nennt 13 Literaturangaben. Gefördert von: Bundesministerium für Bildung und Forschung, DFG Research Infrastructure NGS_CC, EJP RD Joint Transnational Call 2022.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Two adolescent female patients, who were referred independently of each other, presented with progressive gait disturbances that worsened over the course of the day. Symptoms began in early childhood with foot instability and progressed to clubfoot, pain, and limping. MRI of the neuroaxis did not reveal any central nervous system abnormalities. Genetic testing identified the same intronic variant of uncertain significance in GCH1 in both individuals. Subsequent investigations uncovered a previously unrecognized familial relationship between the two patients, belonging to an extended family in which six women were affected by a gait disorder. Previous diagnoses within the family included childhood-onset spasticity and psoriatic arthritis. The familial GCH1 variant was confirmed in all symptomatic individuals, as well as in two asymptomatic female carriers. RNA sequencing revealed a splicing defect caused by the GCH1 near splice-site variant. A robust clinical response to L-DOPA therapy confirmed the diagnosis of DOPA-responsive dystonia (DRD) in this family. This case highlights the phenotypic variability of DRD, which frequently leads to misdiagnosis and delays in appropriate treatment. Careful assessment of family history and recognition of diurnal symptom fluctuations are key to identifying this highly treatable condition.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

GTP CyclohydrolaseDystonic DisordersHumansFemaleAdolescentPedigreeLevodopa

Substanzen

GTP CyclohydrolaseGCH1 protein, humanLevodopa

Autor:innen und Institutionen

  • Department of Pediatric Neurology and Muscle Disorders, University Hospital Freiburg, Freiburg, Germany.
  • Institute of Human Genetics, School of Medicine and Health, Technical University of Munich, Munich, Germany.
  • Institute of Neurogenomics, Helmholtz Zentrum München, Oberschleißheim, Germany.
  • Institute for Advanced Study, Technical University of Munich, Garching, Germany.

ORCID-Profile: Johanna Engel, Wibke G Janzarik

Förderung

  • Bundesministerium für Bildung und Forschung
  • DFG Research Infrastructure NGS_CC
  • EJP RD Joint Transnational Call 2022
  • Else Kröner-Fresenius-Stiftung
  • Technical University of Munich - Institute for Advanced Study
  • Free State of Bavaria
  • Deutsche Forschungsgemeinschaft

Zitieren

APA

Engel, J., Dzinovic, I., Zech, M., & Janzarik, W. G. (2026). Novel Pathogenic GCH1 Variant in Familial DOPA-Responsive Dystonia. Neuropediatrics, 57(01), 065-068. https://doi.org/10.1055/a-2747-7443

Vancouver

Engel J, Dzinovic I, Zech M, Janzarik WG. Novel Pathogenic GCH1 Variant in Familial DOPA-Responsive Dystonia. Neuropediatrics. 2026;57(01):065-068. doi:10.1055/a-2747-7443

BibTeX
@article{Engel2026,
  author = {Engel, Johanna and Dzinovic, Ivana and Zech, Michael and Janzarik, Wibke G},
  title = {Novel Pathogenic GCH1 Variant in Familial DOPA-Responsive Dystonia},
  journal = {Neuropediatrics},
  year = {2026},
  volume = {57},
  number = {01},
  pages = {065--068},
  doi = {10.1055/a-2747-7443}
}
Kostenlos starten →